title: Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction.
abstract: BACKGROUND
  Mitogen-activated protein kinases (MAPKs) have emerged as an important pathophysiologic regulator during the development of heart failure (HF). p38 MAPK activity is elevated in cardiac hypertrophy and HF. We used a mouse model of myocardial infarction (MI) to test the hypotheses that (1) inhibition of p38 MAPK activity may improve cardiac function and remodeling after myocardial infarction (MI) and (2) coadministration of a p38 inhibitor (p38i) and an angiotensin-converting enzyme inhibitor (ACEI) may provide only limited further cardioprotection in this model.
  
  
  RESULTS
  MI was induced in C57BL/6J mice by ligating the left anterior descending coronary artery and then either left untreated or treated with a p38i (SC-409, 30 mg/kg/day in chow), ACEI (enalapril, 20 mg/kg in drinking water), or p38i plus ACEI for 12 weeks. Echocardiography was performed and systolic blood pressure measured before MI and weekly thereafter. At the end of the study, interstitial collagen fraction (ICF) and myocyte cross-sectional area (MCSA) were examined histologically. We found that p38i significantly increased left ventricular ejection fraction and cardiac output and decreased left ventricular area at diastole, ICF, and MCSA. ACEi and p38i each had similar beneficial effects in this mouse model of HF produced by a large MI. Coadministration of p38i and ACEi did not provide any additional benefit.
  
  
  CONCLUSIONS
  Our data suggest that inhibition of p38 MAPK provides significant cardioprotection in mice with HF post-MI.
authors.affiliation: Hypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Hospital, Detroit, MI 48202-2689, USA.
authors.forename: Yun-He
authors.initials: YH
authors.lastname: Liu
authors.forename: Dahai
authors.initials: D
authors.lastname: Wang
authors.forename: Nour-Eddine
authors.initials: NE
authors.lastname: Rhaleb
authors.forename: Xiao-Ping
authors.initials: XP
authors.lastname: Yang
authors.forename: Jiang
authors.initials: J
authors.lastname: Xu
authors.forename: Steadman S
authors.initials: SS
authors.lastname: Sankey
authors.forename: Amy E
authors.initials: AE
authors.lastname: Rudolph
authors.forename: Oscar A
authors.initials: OA
authors.lastname: Carretero
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D002302:Cardiac Output / Q000187:drug effects; D004195:Disease Models, Animal; D006333:Heart Failure / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009203:Myocardial Infarction / Q000150:complications; D015398:Signal Transduction / Q000502:physiology; D016277:Ventricular Function, Left / Q000187:drug effects; D020257:Ventricular Remodeling; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D048051:p38 Mitogen-Activated Protein Kinases